N/A
Manufactured by ANI Pharmaceuticals, Inc.
17,268 FDA adverse event reports analyzed
Last updated: 2026-04-14
PYRAZINAMIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by ANI Pharmaceuticals, Inc.. The most commonly reported adverse reactions for PYRAZINAMIDE include DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, DRUG-INDUCED LIVER INJURY, PYREXIA, DRUG INTERACTION, PARADOXICAL DRUG REACTION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PYRAZINAMIDE.
Out of 9,038 classified reports for PYRAZINAMIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 17,268 FDA FAERS reports that mention PYRAZINAMIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, DRUG-INDUCED LIVER INJURY, PYREXIA, DRUG INTERACTION, PARADOXICAL DRUG REACTION, OFF LABEL USE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list ANI Pharmaceuticals, Inc. in connection with PYRAZINAMIDE. Always verify the specific product and NDC with your pharmacist.